An Abundant Perivascular Source of Stem Cells for Bone Tissue Engineering

作者：James Aaron W; Zara Janette N; Corselli Mirko; Askarinam Asal; Zhou Ann M; Hourfar Alireza; Alan Nguyen; Megerdichian Silva; Asatrian Greg; Pang Shen; Stoker David; Zhang Xinli; Wu Benjamin; Ting Kang^*; Peault Bruno; Soo Chia

来源：Stem Cells Translational Medicine, 2012, 1(9): 673-684.

DOI：10.5966/sctm.2012-0053

• Adult stem cells
• CD34+
• Cell biology
• Cell surface markers
• Cell transplantation
• Cellular therapy
• Mesenchymal stem cells
• Osteoblast

Adipose tissue is an ideal mesenchymal stem cell (MSC) source, as it is dispensable and accessible with minimal morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which has disadvantages for tissue regeneration. In the present study, we prospectively purified human perivascular stem cells (PSCs) from n = 60 samples of human lipoaspirate and documented their frequency, viability, and variation with patient demographics. PSCs are a fluorescence-activated cell sorting-sorted population composed of pericytes (CD45-, CD146+, CD34-) and adventitial cells (CD45-, CD146-, CD34+), each of which we have previously reported to have properties of MSCs. Here, we found that PSCs make up, on average, 43.2% of SVF from human lipoaspirate (19.5% pericytes and 23.8% adventitial cells). These numbers were minimally changed by age, gender, or body mass index of the patient or by length of refrigerated storage time between liposuction and processing. In a previous publication, we observed that human PSCs (hPSCs) formed significantly more bone in vivo in comparison with unsorted human SVF (hSVF) in an intramuscular implantation model. We now extend this finding to a bone injury model, observing that purified hPSCs led to significantly greater healing of mouse critical-size calvarial defects than hSVF (60.9% healing as opposed to 15.4% healing at 2 weeks postoperative by microcomputed tomography analysis). These studies suggest that adipose-derived hPSCs are a new cell source for future efforts in skeletal regenerative medicine. Moreover, hPSCs are a stem cell-based therapeutic that is readily approvable by the U.S. Food and Drug Administration, with potentially increased safety, purity, identity, potency, and efficacy. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:673-684

• 出版日期2012-9